GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Total Liabilities

Nutriband (Nutriband) Total Liabilities : $1.08 Mil (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Nutriband Total Liabilities?

Nutriband's Total Liabilities for the quarter that ended in Jan. 2024 was $1.08 Mil.

Nutriband's quarterly Total Liabilities declined from Jul. 2023 ($2.98 Mil) to Oct. 2023 ($2.81 Mil) and declined from Oct. 2023 ($2.81 Mil) to Jan. 2024 ($1.08 Mil).

Nutriband's annual Total Liabilities increased from Jan. 2022 ($0.88 Mil) to Jan. 2023 ($0.88 Mil) and increased from Jan. 2023 ($0.88 Mil) to Jan. 2024 ($1.08 Mil).


Nutriband Total Liabilities Historical Data

The historical data trend for Nutriband's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband Total Liabilities Chart

Nutriband Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 2.02 2.82 0.88 0.88 1.08

Nutriband Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.96 2.98 2.81 1.08

Nutriband Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nutriband's Total Liabilities for the fiscal year that ended in Jan. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.999+(0.08+-4.1633363423443E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.08

Total Liabilities=Total Assets (A: Jan. 2024 )-Total Equity (A: Jan. 2024 )
=7.517-6.438
=1.08

Nutriband's Total Liabilities for the quarter that ended in Jan. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.999+(0.08+-4.1633363423443E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.08

Total Liabilities=Total Assets (Q: Jan. 2024 )-Total Equity (Q: Jan. 2024 )
=7.517-6.438
=1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nutriband Total Liabilities Related Terms

Thank you for viewing the detailed overview of Nutriband's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Nutriband (Nutriband) Business Description

Traded in Other Exchanges
Address
121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801
Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Executives
Michael Davidov director 60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan director, 10 percent owner, officer: CEO 6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros director, 10 percent owner, officer: Chairman of the BOD GREGERSTR 36B, FISHAMEND C4 2401